B-cell Chronic Lymphocytic Leukemia Clinical Trial
Official title:
A Phase II Study of Fludarabine + Rituximab Induction Followed by Alemtuzumab (Campath-1H, NSC #715969, IND #10864) Administered Subcutaneously as Consolidation in Untreated Patients With B-Cell Chronic Lymphocytic Leukemia
This phase II trial is studying how well giving fludarabine together with rituximab followed by alemtuzumab works in treating patients with chronic lymphocytic leukemia. Monoclonal antibodies, such as rituximab and alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others can find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving fludarabine together with rituximab followed by alemtuzumab may kill more cancer cells.
PRIMARY OBJECTIVES:
I. To determine the rate of complete response and toxicity of concurrent treatment with
fludarabine and rituximab followed by consolidative alemtuzumab in patients with previously
untreated, but symptomatic, CLL.
II. To determine if alemtuzumab improves the CR rate with acceptable toxicity when
administered as consolidation therapy following induction therapy with fludarabine and
rituximab.
III. To estimate the progression-free and overall survival of high risk (VH gene unmutated
and those with p53 dysfunction) and low-risk (others) patients following therapy with
fludarabine and rituximab induction and consolidative alemtuzumab.
IV. To determine the frequency of molecular (PCR) remission following fludarabine and
rituximab induction therapy and alemtuzumab consolidation therapy and if this serves as a
surrogate marker for prolonged progression-free and overall survival.
SECONDARY OBJECTIVES:
I. To determine the effect of concurrent treatment with fludarabine and rituximab followed
by consolidative alemtuzumab on recovery of T-cells, NK cells, and serum immunoglobulin
levels.
II. To determine clinical and molecular features that predict for poor response to
fludarabine and rituximab induction and subsequent alemtuzumab consolidation therapy.
III. To assess preliminarily the molecular features of CLL at relapse in patients responding
to chemoimmunotherapy for CLL.
IV. To determine the frequency of patients who remain at high risk for progression of CLL
despite this therapy and who are thus eligible for nonmyeloablative stem cell
transplantation studies such as CALGB 109901.
V. To perform limited rituximab pharmacokinetics to determine the ideal schedule of
administration for a subsequent rituximab maintenance treatment approach following induction
therapy with fludarabine and rituximab.
OUTLINE:
Patients receive induction therapy comprising rituximab IV over 4 hours on days 1, 3, and 5
of course 1 and day 1 of all subsequent courses and fludarabine IV over 30 minutes on days
1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease
progression.
Approximately 4 months after completion of induction therapy, patients achieving a partial
response, nodular partial response, or stable disease receive consolidation therapy
comprising alemtuzumab subcutaneously on days 1-3. Treatment repeats weekly for up to 6
courses in the absence of disease progression.
Patients are followed at 2 months, every 3 months for 1 year, and then every 6 months for 7
years from study entry.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03204188 -
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
|
Phase 2 | |
Terminated |
NCT00377104 -
Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
Phase 1 | |
Completed |
NCT00006226 -
Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
|
Phase 2 | |
Completed |
NCT01576588 -
Rituximab in Pretreated Elderly or Unfit B-CLL Patients
|
Phase 2 | |
Completed |
NCT01212380 -
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
|
Phase 1 | |
Terminated |
NCT00288067 -
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT00910910 -
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)
|
Phase 3 | |
Recruiting |
NCT03110640 -
Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma
|
Phase 1 | |
Terminated |
NCT00101205 -
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
|
Phase 1 | |
Completed |
NCT00005799 -
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
|
N/A | |
Terminated |
NCT02440685 -
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT01126502 -
Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT01105247 -
Safety of PCI-32765 in Chronic Lymphocytic Leukemia
|
Phase 1/Phase 2 | |
Completed |
NCT00321724 -
AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
|
Phase 2 | |
Completed |
NCT02381080 -
Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
|
Phase 1 | |
Completed |
NCT04030195 -
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00918450 -
Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen
|
Phase 2 | |
Terminated |
NCT00302861 -
A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL)
|
Phase 1/Phase 2 | |
Completed |
NCT00290472 -
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 2 | |
Completed |
NCT00565981 -
A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response
|
Phase 2 |